MedTrace Logo

The Effects of a Multicomponent Sleep & Recovery Supplement on Muscle Fatigue and Sleep

NCT07756164 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-08-10

No results posted yet for this study

Summary

The goal of this clinical trial (randomised crossover study) is to learn if a multi-component sleep and exercise recovery supplement can improve sleep quality and enhance recovery following exercise in healthy, recreationally active adults aged 18-40.

The main questions it aims to answer are:

1. Does the supplement reduce delayed onset muscle soreness (DOMS) following an intense exercise protocol?
2. Does the supplement improve sleep quality?

Researchers will compare the supplement to a placebo (a look-alike tablet with no active ingredients) to see if the supplement improves exercise recovery and sleep quality. In this crossover design, all participants will receive both the supplement and the placebo in separate 2-week periods, with a 2-week washout period in between.

Participants will:

* Take the supplement during one 2-week period and the placebo during another (order randomised), 30 minutes before bed each day
* Complete an exercise protocol involving repeated leg extensions designed to induce muscle fatigue
* Attend six laboratory visits, including baseline testing and follow-up assessments at 24 and 48 hours post-exercise
* Complete daily sleep questionnaires during each supplementation period
* Record food intake prior to exercise trials and replicate it for consistency
* Perform muscle soreness assessments and single-leg jump tests before and after exercise, and during recovery

Conditions

  • Athletes
  • Healthy

Interventions

DIETARY_SUPPLEMENT

magnesium-based sleep & recovery supplement

magnesium-based sleep \& recovery supplement (2g/day for 2-weeks)

DIETARY_SUPPLEMENT

Placebo Supplementation

Placebo Supplementation (2g/day for 2-weeks)

Sponsors & Collaborators

  • University of Exeter

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2026-10-31
Completion
2026-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07756164 on ClinicalTrials.gov